NCT04398004 - Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

COVID-19Virus DiseasesCorona Virus Infection

Interventions

DRUG

Clarithromycin

Treatment with 500 mg Clarithromycin orally twice daily for seven days

Trial Locations (9)

1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens

2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens

3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens

COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi

2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus

"2nd Department of Internal Medicine, General Hospital of Piraeus Tzaneio", Piraeus

1st Department of Internal Medicine, General University Hospital of Ioannina, Ioannina

1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki

2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupoli

All Listed Sponsors

lead

Hellenic Institute for the Study of Sepsis

OTHER